B. Riley analyst Madison El-Saadi raised the firm’s price target on Arrowhead (ARWR) to $101 from $61 and keeps a Buy rating on the shares. Positive siRNA-INHBE data and Arrowhead developments sufficiently de-risk INHBE biology, supporting conviction in Arrowhead ahead of a catalyst-heavy period with expected quarterly updates, the analyst tells investors in a research note. The name appears significantly undervalued relative to recent obesity M&A comps, the firm says.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $100 from $85 at H.C. Wainwright
- Arrowhead price target raised to $110 from $100 at Piper Sandler
- Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
- Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
- Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings